The Alzheimer's Disease Research Center at the University of California, Irvine

加州大学欧文分校阿尔茨海默病研究中心

基本信息

批准号：
10747262
负责人：
FRANK M LAFERLA
金额：
$ 0.61万
依托单位：
UNIVERSITY OF CALIFORNIA-IRVINE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-15 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10747262
关键词：
Address Adult Age Aged, 80 and over Alzheimer&apos s Disease Alzheimer&apos s disease pathology Alzheimer&apos s disease risk Autopsy Basic Science Biological Markers Brain Diseases California Clinical Clinical Sciences Cognitive Communities Consent County Data Data Set Development Diagnosis Dimensions Disease Disparity Down Syndrome Education Epidemic Ethnic Population Etiology Goals Image Impaired cognition Individual Knowledge Longevity Modernization Nature Oranges Outcome Pathogenesis Pathologic Patients Persons Populations at Risk Predisposition Productivity Recording of previous events Registries Research Research Personnel Resources Scientist Special Population Stains Training Translational Research Universities cell bank cohort in vivo induced pluripotent stem cell innovation insight interdisciplinary approach mild cognitive impairment neuropathology next generation novel prevent prodromal Alzheimer&apos s disease recruit resilience

项目摘要

UCI ADRC Overall Project Summary/Abstract The central theme of the University of California, Irvine Alzheimer's Disease Research Center (UCI ADRC) is to identify, quantify, and validate factors that influence the risk of Alzheimer's disease (AD) across the lifespan. Given its diverse and multifactorial nature, it is critical to understand the etiology and progression of this insidious brain disorder at multiple dimensions, including clinically and neuropathologically, and to employ novel scientific approaches so that we can advance knowledge and better diagnose, prevent and cure the disease. The UCI ADRC has a strong history of integrating basic, clinical, and translational science to gain insights into AD pathogenesis and to help meet some of the goals of the National Alzheimer's Project Act. First, our Center has a distinguished record of studying the disease in diverse patient cohorts: Uniform Data Set (UDS) Cohort, which includes cognitively normal individuals and individuals with mild cognitive impairment (prodromal AD); adults with Down syndrome, representing the largest genetically at-risk population for AD; and 90+, which show great disparity between AD pathology and cognitive loss and are among the oldest group of individuals to develop AD. Together, these cohorts enable interrogation of important novel questions related to age, susceptibility and resilience, using innovative outcomes ranging from in vivo biomarker characterization to modern pathological outcomes such as post-mortem imaging and microglial staining. Second, the UCI ADRC has a history of innovation that has helped advance the field; the development of the nation's first induced pluripotent stem cell bank for AD as part of the ADRC network and our recently established Consent-to- Contact recruitment registry are recent examples of this innovation. Third, our Center continues to evolve. Given the expertise, productivity, and resources devoted the study of special populations at UCI, we have initiated two Special Populations Cores, one focused on Down syndrome and one focused on the oldest old (90+). These Cores will interact with the other cores of the ADRC to produce novel data and resources available to ADRC investigators, including through our newly established Biomarker Core. Finally, we have established a new Research and Education Component in this proposal, which harnesses the long-standing passionate commitment to training the next generation of clinicians and scientists at UCI. In sum, the UCI ADRC brings energetic and innovative multi-dimensional and multidisciplinary approaches toward addressing the national epidemic of AD.

UCI ADRC 整体项目概要/摘要加州大学欧文分校阿尔茨海默病研究中心 (UCI ADRC) 的中心主题是识别、量化和验证影响整个生命周期阿尔茨海默病 (AD) 风险的因素。鉴于其多样性和多因素性质，了解其病因和进展至关重要多个维度的隐匿性脑部疾病，包括临床和神经病理学，并采用新颖的科学方法，使我们能够增进知识并更好地诊断、预防和治疗疾病。 UCI ADRC 在整合基础、临床和转化科学方面有着悠久的历史，以获得深入了解 AD 发病机制并帮助实现国家阿尔茨海默病项目法案的一些目标。首先，我们中心在研究不同患者群体的疾病方面拥有杰出的记录：统一数据 Set (UDS) 队列，包括认知正常个体和轻度认知障碍个体（AD前驱期）；患有唐氏综合症的成年人，代表了最大的 AD 遗传风险人群；和 90岁以上，显示AD病理和认知丧失之间存在巨大差异，是最古老的群体之一个人发展AD。这些群体共同探讨与以下相关的重要新问题：年龄、易感性和恢复力，利用从体内生物标志物表征到现代病理结果，例如尸检成像和小胶质细胞染色。二、UCI ADRC 拥有帮助推动该领域发展的创新历史；全国首创研发 AD 多能干细胞库作为 ADRC 网络的一部分以及我们最近建立的同意书联系招聘登记处是这一创新的最新例子。第三，我们的中心不断发展。鉴于 UCI 专门用于特殊人群研究的专业知识、生产力和资源，我们启动了两项特殊人群核心项目，一项重点关注唐氏综合症，另一项重点关注高龄老人（90+）。这些核心将与 ADRC 的其他核心进行交互，以产生新颖的数据和资源可供 ADRC 研究人员使用，包括通过我们新建立的生物标记核心。最后，我们有在该提案中建立了一个新的研究和教育部分，该部分利用了长期存在的加州大学尔湾分校 (UCI) 热衷于培训下一代临床医生和科学家。总而言之，UCI ADRC 带来了充满活力和创新的多维度和多学科方法来解决全国范围内的AD流行。